DGK-η inhibitors are a class of chemical compounds specifically designed to target and modulate the activity of the diacylglycerol kinase eta (DGK-η) enzyme, an important member of the diacylglycerol kinase (DGK) family. DGK-η plays a crucial role in lipid signaling by catalyzing the phosphorylation of diacylglycerol (DAG) to produce phosphatidic acid (PA). Both DAG and PA are vital lipid signaling molecules involved in regulating various cellular processes, including cell proliferation, differentiation, and immune responses. By controlling the conversion of DAG to PA, DGK-η influences the balance between these two signaling molecules, thereby modulating downstream signaling pathways. Inhibitors of DGK-η are developed to interfere with its enzymatic activity, effectively altering the levels of DAG and PA and providing a tool to study the specific roles of DGK-η in cellular signaling networks.
The development of DGK-η inhibitors involves a detailed structural and functional analysis of the enzyme, particularly focusing on its active site and the regions involved in substrate binding and catalysis. Structural biology techniques such as X-ray crystallography, cryo-electron microscopy, and nuclear magnetic resonance (NMR) spectroscopy are utilized to determine the three-dimensional structure of DGK-η. This structural information is crucial for identifying the binding sites and catalytic domains that are essential for the enzyme's function. Computational methods, including molecular docking and virtual screening, are employed to identify small molecules that can specifically bind to these sites, thereby inhibiting DGK-η's catalytic activity with high affinity and specificity. Once potential inhibitors are identified, they undergo synthesis and in vitro testing to assess their binding affinity, specificity, and inhibitory potency. These inhibitors are further optimized through iterative cycles of chemical refinement to enhance their effectiveness, stability, and selectivity. The study of DGK-η inhibitors not only provides valuable insights into the enzyme's role in lipid signaling but also contributes to a broader understanding of how lipid-mediated signal transduction influences various cellular processes and the overall regulatory mechanisms that govern cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R 59-022 | 93076-89-2 | sc-203227 | 5 mg | $122.00 | 1 | |
General DGK inhibitor with a role in preventing PA formation. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $336.00 $1642.00 | 20 | |
Interferes with the action of DGKs through DAG binding site competition. | ||||||
Ritanserin | 87051-43-2 | sc-203681 sc-203681A | 10 mg 50 mg | $87.00 $306.00 | 2 | |
While known as a 5-HT receptor antagonist, it can also inhibit DGK. | ||||||
1-Oleoyl-2-acetyl-sn-glycerol (OAG) | 86390-77-4 | sc-200417 sc-200417A | 10 mg 50 mg | $117.00 $444.00 | 1 | |
A DAG analog that can compete with DAG, affecting DGK activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Although a broad kinase inhibitor, it affects DGK among others. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $88.00 $190.00 $500.00 $2400.00 $9200.00 $15000.00 | 2 | |
Competes with DAG for binding, modulating DGK activity. | ||||||